SCHEMBL16900643

SCHEMBL16900643

O=[N+]([O-])c1ccccc1N1CCN(O)CC1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.63
KMT2A Q03164 3/20 0.63
GRM5 P41594 1/20 0.57
MAPT P10636 7/20 0.56
LMNA P02545 4/20 0.56
L3MBTL1 Q9Y468 3/20 0.56
MAPK1 P28482 2/20 0.56
ALDH1A1 P00352 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
MITF O75030 1/20 0.56
CCR6 P51684 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
MEN1 O00255 2/20 0.54
GAA P10253 2/20 0.54
HSD11B1 P28845 1/20 0.52
FAAH O00519 1/20 0.52
MGLL Q99685 1/20 0.52
ENPP2 Q13822 4/20 0.51
DRD4 P21917 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1274938 0.91 HTT (0.73) HTTKMT2AGRM5MAPTLMNA
SCHEMBL29937743 0.84 CTSB (0.65) HTTKMT2AGRM5MAPTLMNA
SCHEMBL7118705 0.84 HTT (0.64) HTTKMT2AGRM5MAPTLMNA
SCHEMBL3799173 0.84 CTSB (0.65) HTTKMT2AGRM5MAPTLMNA
SCHEMBL3064690 0.83 HTT (0.68) HTTKMT2AGRM5MAPTLMNA
SCHEMBL29426374 0.83 HTT (0.68) HTTKMT2AGRM5MAPTLMNA
SCHEMBL13790192 0.83 HTT (0.63) HTTKMT2AGRM5MAPTLMNA
SCHEMBL29738367 0.82 GAA (0.63) HTTKMT2AMAPTLMNAL3MBTL1
SCHEMBL3292356 0.82 GAA (0.63) HTTKMT2AMAPTLMNAL3MBTL1
SCHEMBL4526192 0.82 GRM5 (0.67) HTTKMT2AGRM5MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015107057-A1 SYNTHESIS OF VORTIOXETINE VIA (2-(PIPERAZINE-1 -YL)PHENYL)ANILINE INTERMEDIATES LEK PHARMACEUTICALS D.D. (SI) 2015-07-23 WO disclosed
EP-2894154-A1 Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)aniline intermediates LEK Pharmaceuticals d.d. (SI) 2015-07-15 EP disclosed